STAAR Surgical stock falls 5.2 percent as valuation gap widens

STAAR Surgical Company stock (ISIN US8577001096) closed at USD 21.24 on September 17, 2026, after a 5.2 percent decline that pushed the shares further below many valuation models for the ophthalmic implant specialist. According to GuruFocus on September 17, 2026, the stock traded at USD 21.24 against a proprietary GF Value estimate of USD 33.38, implying an undervaluation of 36.4 percent.

Valuation gap after latest price drop

The 5.2 percent decline on September 17, 2026, left STAAR Surgical stock near the lower end of its recent trading range and underscored a widening gap between market price and fundamental valuation metrics. As GuruFocus reports, STAAR shares have traded in a 52-week range between USD 15.59 and USD 35.87, placing the September 17 closing price of USD 21.24 much closer to the low than to the high. In that context, the difference between the USD 21.24 market price and the USD 33.38 GF Value estimate represents a discount of 36.4 percent to the modelled fair value.

For investors, this quantified spread between price and estimated value is central to the current debate on STAAR Surgical stock. The 52-week high of USD 35.87 stands 68.9 percent above the 52-week low of USD 15.59, while the current price of USD 21.24 is roughly USD 14.63 below the GF Value figure of USD 33.38, emphasizing how far the shares now sit beneath one widely followed fundamental benchmark. According to GuruFocus, the proprietary GF Value framework considers historical multiples, past returns and growth, and future business performance estimates to arrive at its USD 33.38 fair value for STAAR.

Business profile and recent fundamentals

STAAR Surgical Company focuses on implantable lenses used in refractive surgery to correct vision, especially its proprietary EVO ICL lens family marketed for the correction of myopia and astigmatism. According to company information presented on its investor relations site STAAR Surgical Company, the group positions itself as a technology-driven medical device manufacturer with a focus on minimally invasive ophthalmic implants rather than traditional laser-based procedures.

While the most recent quarterly figures are not explicitly detailed in the week-filtered sources available up to September 18, 2026, STAAR Surgical’s valuation metrics as described by GuruFocus highlight a business with a history of growth, profitability and a solid balance sheet. The GF Value model assumes that STAAR’s current revenue base and margins can support a higher fair value than the prevailing market price, even if recent share price performance has been volatile.

Historically, STAAR Surgical has reported double-digit revenue growth in successive years as it expanded adoption of its EVO ICL lenses in Asia, Europe and the United States. In prior fiscal years, the company disclosed rising sales of implantable collamer lenses and improving gross margins as it scaled manufacturing and broadened its geographic reach, though those historical numbers now serve mainly as a backdrop to the current price and valuation debate rather than as fresh core figures for 2026.

Risk factors in the current setup

The discount to GF Value does not eliminate the operational and market risks that STAAR Surgical stock carries. According to GuruFocus, the company operates in a competitive ophthalmic device landscape where it must contend with established laser vision correction technologies and rival implantable lens makers. Regulatory requirements for medical devices, reimbursement dynamics in key markets and the need to maintain high manufacturing and quality standards all represent structural risks.

Shorter term, the volatility seen in STAAR Surgical stock over its 52-week range illustrates how quickly sentiment can shift around niche medical device companies. The movement from USD 35.87 at the 52-week high down to USD 21.24 as of September 17, 2026, marks a decline of USD 14.63, or 40.8 percent, from the high to the current closing price. This journey suggests that investor enthusiasm has cooled markedly since the peak, even though valuation models such as GF Value indicate upside relative to fundamentals. For holders of STAAR Surgical stock, the balance between potential valuation-driven gains and the risk of further volatility remains a key consideration.

STAAR Surgical stock on Nasdaq

STAAR Surgical Company is listed on Nasdaq in the United States under the ticker symbol STAA, with the shares quoted in USD. The reference price for the stock in this article is the Nasdaq closing level of USD 21.24 on September 17, 2026, which reflects the 5.2 percent decline reported by GuruFocus. At that level, the shares sit well below the 52-week high of USD 35.87 and above the 52-week low of USD 15.59.

More news and analyses on STAAR Surgical Company stock